These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33097612)

  • 21. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
    Autio KA; Klebanoff CA; Schaer D; Kauh JSW; Slovin SF; Adamow M; Blinder VS; Brahmachary M; Carlsen M; Comen E; Danila DC; Doman TN; Durack JC; Fox JJ; Gluskin JS; Hoffman DM; Kang S; Kang P; Landa J; McAndrew PF; Modi S; Morris MJ; Novosiadly R; Rathkopf DE; Sanford R; Chapman SC; Tate CM; Yu D; Wong P; McArthur HL
    Clin Cancer Res; 2020 Nov; 26(21):5609-5620. PubMed ID: 32847933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
    Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
    J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
    Coveler AL; Smith DC; Phillips T; Curti BD; Goel S; Mehta AN; Kuzel TM; Markovic SN; Rixe O; Bajor DL; Gajewski TF; Gutierrez M; Lee HJ; Gopal AK; Caimi P; Heath EI; Thompson JA; Ansari S; Jacquemont C; Topletz-Erickson A; Zhou P; Schmitt MW; Grilley-Olson JE
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
    Geva R; Voskoboynik M; Dobrenkov K; Mayawala K; Gwo J; Wnek R; Chartash E; Long GV
    Cancer; 2020 Nov; 126(22):4926-4935. PubMed ID: 32809217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
    Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
    J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
    Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
    Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
    Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
    Delgado R; Kielbassa K; Ter Burg J; Klein C; Trumpfheller C; de Heer K; Kater AP; Eldering E
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
    Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
    J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
    Siu L; Brody J; Gupta S; Marabelle A; Jimeno A; Munster P; Grilley-Olson J; Rook AH; Hollebecque A; Wong RKS; Welsh JW; Wu Y; Morehouse C; Hamid O; Walcott F; Cooper ZA; Kumar R; Ferté C; Hong DS
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.
    Pradel LP; Ooi CH; Romagnoli S; Cannarile MA; Sade H; Rüttinger D; Ries CH
    Mol Cancer Ther; 2016 Dec; 15(12):3077-3086. PubMed ID: 27582524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
    Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
    [No Abstract]   [Full Text] [Related]  

  • 39. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
    Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
    Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.
    Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA
    Immunotherapy; 2024; 16(11):759-774. PubMed ID: 39264730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.